Nontuberculous Mycobacterial Infection Market Report Examines Leading Companies And Growth Opportunities

The market for nontuberculous mycobacterial (NTM) infections is on track for significant expansion in the coming years, driven by advances in treatment options and diagnostic technologies. As healthcare continues to evolve with personalized therapies and AI-powered tools, this sector is receiving increased attention from pharmaceutical companies and medical institutions alike. Below is an overview of the market's projected growth, major players, emerging trends, and segment details that shape the future of NTM infection management.

Projected Market Size and Growth Trajectory of the Nontuberculous Mycobacterial Infection Market
The nontuberculous mycobacterial infection market is anticipated to experience robust growth, reaching a valuation of $21.01 billion by 2030. This corresponds to a compound annual growth rate (CAGR) of 7.3% during the forecast period. Key contributors to this upward trend include the broader acceptance of macrolide and rifampin combination therapies, increased accessibility of aminoglycosides, the rise of personalized treatment strategies, expansion of hospital and specialty pharmacy networks, and the development of AI-enabled diagnostic and monitoring technologies. The market is also being shaped by trends such as the growing preference for combination drug regimens, wider use of aminoglycoside treatments, and the integration of sophisticated AI-powered tools for better monitoring and diagnosis.

The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $14.96 billion in 2025 to $15.87 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to high incidence of pulmonary infections, limited effective therapies, delayed diagnosis of nontuberculous mycobacteria, reliance on conventional antibiotic regimens, low awareness among clinicians.

Download a free sample of the nontuberculous mycobacterial infection market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Driving Forces Behind the Nontuberculous Mycobacterial Infection Market Growth
One major factor fueling market expansion is the rising adoption of combination therapies involving macrolides and rifampin, which have shown promising effectiveness in treating NTM infections. These therapeutic advances are helping clinicians address the complexities of these infections more efficiently. Additionally, the increased availability and use of aminoglycosides-antibiotics known for their potency against certain bacterial strains-are further strengthening treatment outcomes.

The market is also benefiting from the introduction of personalized medicine approaches that tailor treatment to individual patient needs. This shift enhances patient compliance and effectiveness of therapies. Meanwhile, expanding hospital and specialty pharmacy networks are improving access to these advanced medications. The growing application of AI-driven tools for diagnosis and treatment monitoring is another vital factor supporting market growth by enabling earlier and more accurate detection of NTM infections.

View the full nontuberculous mycobacterial infection market report:
https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Key Industry Players in the Nontuberculous Mycobacterial Infection Market
The competitive landscape of the nontuberculous mycobacterial infection market includes several prominent pharmaceutical companies. Leading firms in this space include Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Lupin Limited, Insmed Incorporated, Paratek Pharmaceuticals Inc., and Spero Therapeutics Inc. Other significant contributors include Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC, Savara Inc., Mannkind Corporation, Matinas BioPharma Holdings Inc., Vast Therapeutics Inc., Crestone Inc., AN2 Therapeutics Inc., Revimmune Inc., Shionogi Co Ltd, Summit Therapeutics plc, BioVersys AG, RedHill Biopharma Ltd, Shanghai MicuRx Pharmaceutical Co Ltd, Otsuka Pharmaceutical Co Ltd, Cipla Limited, and Daiichi Sankyo Company Ltd.

A notable recent collaboration took place in February 2023 when Korea-based biotech firm Qurient Co. Ltd. entered into a partnership with TB Alliance. Together, they aim to develop telacebec, a novel drug targeting tuberculosis and other NTM infections. Under this agreement, TB Alliance will receive the exclusive global license to continue development and international marketing of telacebec. TB Alliance is a South Africa-based nonprofit organization dedicated to creating affordable TB treatments globally.

Emerging Trends and Innovations Creating Opportunities in the Nontuberculous Mycobacterial Infection Market
Innovative treatment approaches are at the forefront of advancing NTM infection care. Many companies are focusing on developing boron-based antibiotics, which are small-molecule therapies designed to inhibit bacterial protein synthesis. These antibiotics offer promising advantages such as enhanced effectiveness, reduced drug resistance, and improved patient safety compared to traditional treatments.

For example, in September 2023, US-based biopharmaceutical company AN2 Therapeutics began enrolling patients in the Phase 3 portion of its pivotal Phase 2/3 clinical trial for epetraborole. This drug targets treatment-resistant Mycobacterium avium complex lung disease. Epetraborole is administered orally and has shown encouraging preclinical results against Mycobacterium abscessus infections. Its development hopes to shorten treatment durations, increase tolerability, and meet unmet needs in rare and severe infectious lung diseases, ultimately aiming to improve patient outcomes.

Segments That Capture the Largest Share of the Nontuberculous Mycobacterial Infection Market
This market is segmented by drug class, route of administration, and distribution channel. The drug classes include macrolides, rifampin, aminoglycosides, and other drugs. Under macrolides, popular options are azithromycin, clarithromycin, and erythromycin. Rifampin is further divided into rifampin monotherapy, rifampin combination therapy, and extended-duration rifampin therapy. Aminoglycosides include amikacin, streptomycin, and tobramycin. Other drug classes consist of fluoroquinolones, ethambutol, linezolid, and clofazimine.

Routes of administration cover oral, parenteral, and other methods. Distribution channels involve hospital pharmacies, retail pharmacies, and online pharmacies. This detailed segmentation helps stakeholders better understand market dynamics and target specific areas for growth and innovation.

The 2026 edition of our market reports now delivers enhanced analytical coverage through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.